These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 8528638

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intermittent adjuvant chemo-immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis.
    Suzuki M, Kimura H, Iwai N, Fujisawa T.
    Oncol Rep; 2000; 7(3):545-9. PubMed ID: 10767366
    [Abstract] [Full Text] [Related]

  • 5. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer.
    Yano T, Sugio K, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Yoshino I, Sugimachi K.
    Lung Cancer; 1999 Dec; 26(3):143-8. PubMed ID: 10598924
    [Abstract] [Full Text] [Related]

  • 6. [Postsurgical adjuvant immunotherapy against primary non-small cell lung cancer].
    Kimura H, Iwai N, Suzuki M, Takahashi Y.
    Nihon Geka Gakkai Zasshi; 1998 May; 99(5):279-84. PubMed ID: 9656236
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [Abstract] [Full Text] [Related]

  • 9. Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer.
    Kimura H, Matsui Y, Ishikawa A, Nakajima T, Iizasa T.
    Cancer Immunol Immunother; 2018 Aug; 67(8):1231-1238. PubMed ID: 29855695
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.
    Kimura H, Matsui Y, Ishikawa A, Nakajima T, Yoshino M, Sakairi Y.
    Cancer Immunol Immunother; 2015 Jan; 64(1):51-9. PubMed ID: 25262164
    [Abstract] [Full Text] [Related]

  • 11. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M, Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan).
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [Abstract] [Full Text] [Related]

  • 12. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
    Saka H, Kitagawa C, Ichinose Y, Takenoyama M, Ibata H, Kato T, Takami K, Yamashita M, Maeda T, Takeo S, Ueda H, Okabayashi K, Nagashima S, Oka T, Kouso H, Fukuyama S, Yoshimoto K, Shimokawa M, Saito AM, Ito S.
    Trials; 2017 Sep 15; 18(1):429. PubMed ID: 28915900
    [Abstract] [Full Text] [Related]

  • 13. [Adoptive immunotherapy with LAK cell and IL-2 against primary lung cancer].
    Kimura H, Yamaguchi Y.
    Nihon Geka Gakkai Zasshi; 1989 Sep 15; 90(9):1459-62. PubMed ID: 2586439
    [Abstract] [Full Text] [Related]

  • 14. Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer.
    Zhukova OS, Gerasimova GK, Shubina IZh, Kiselevskii MV.
    Bull Exp Biol Med; 2007 Aug 15; 144(2):231-4. PubMed ID: 18399288
    [Abstract] [Full Text] [Related]

  • 15. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients.
    Kimura H, Iizasa T, Ishikawa A, Shingyouji M, Yoshino M, Kimura M, Inada Y, Matsubayashi K.
    Anticancer Res; 2008 Aug 15; 28(2B):1229-38. PubMed ID: 18505060
    [Abstract] [Full Text] [Related]

  • 16. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H.
    Lancet Oncol; 2015 Feb 15; 16(2):187-99. PubMed ID: 25601342
    [Abstract] [Full Text] [Related]

  • 17. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar 15; 82(3):395-404. PubMed ID: 2072602
    [Abstract] [Full Text] [Related]

  • 18. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K, Fujioka T.
    Nihon Hinyokika Gakkai Zasshi; 1993 May 15; 84(5):831-40. PubMed ID: 8320888
    [Abstract] [Full Text] [Related]

  • 19. A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects.
    Yano T, Ishida T, Yoshino I, Murata M, Yasumoto K, Kimura G, Nomoto K, Sugimachi K.
    Biotherapy; 1991 May 15; 3(3):245-51. PubMed ID: 1854593
    [Abstract] [Full Text] [Related]

  • 20. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    Bellone G, Novarino A, Vizio B, Brondino G, Addeo A, Prati A, Giacobino A, Campra D, Fronda GR, Ciuffreda L.
    Int J Oncol; 2009 Jun 15; 34(6):1701-15. PubMed ID: 19424589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.